Login / Signup

Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.

Sarah K ChenKatherine P LiaoJun LiuSeoyoung C Kim
Published in: Arthritis care & research (2019)
In this large cohort of patients with RA who initiated treatment with abatacept or TNFi as a first- or second-line biologic agent, we found a lower risk of hospitalized infection after initiating abatacept versus TNFi, which was driven mostly by infliximab.
Keyphrases
  • rheumatoid arthritis
  • disease activity
  • ankylosing spondylitis
  • interstitial lung disease
  • rheumatoid arthritis patients
  • systemic lupus erythematosus
  • systemic sclerosis
  • replacement therapy